Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shanghai Henlius Biotech, Inc. has initiated dosing of the first patient in mainland China for an international phase 3 clinical trial comparing HLX78 (lasofoxifene) and abemaciclib against fulvestrant and abemaciclib for treating advanced breast cancer. This marks a significant step in Henlius’s efforts to develop innovative cancer treatments, with the trial being conducted globally by Sermonix Pharmaceuticals. The study aims to evaluate the efficacy and safety of the drug combinations in patients with specific genetic mutations.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.